中医药干预慢性阻塞性肺疾病蛋白酶-抗蛋白酶失衡机制的研究进展  

Mechanism of TCM Intervention in Protease-antiprotease Imbalance in Chronic Obstructive Pulmonary Disease:A Review

作　　者：徐梦娇 王海强 汪伟[1] 刘惠梅 李莉[2] 晏军[2] 高峰[1] XU Mengjiao;WANG Haiqiang;WANG Wei;LIU Huimei;LI Li;YAN Jun;GAO Feng(Wangjing Hospital,China Academy of Chinese Medical Sciences,Beijing 100102,China;Dongzhimen Hospital of Beijing University of Chinese Medicine,Beijing 100700,China)

机构地区：[1]中国中医科学院望京医院,北京100102 [2]北京中医药大学东直门医院,北京100700

出　　处：《世界中医药》2024年第10期1500-1504,1509,共6页World Chinese Medicine

基　　金：国家自然科学基金项目(82205036);中国中医科学院科技创新工程资助项目(CI2021A01102);中国中医科学院望京医院院级科研课题(WJYY2020-20)。

摘　　要：慢性阻塞性肺疾病(COPD)的发病机制涉及炎症反应、氧化应激、蛋白酶/抗蛋白酶系统失衡等,其中蛋白酶与抗蛋白酶系统失衡为COPD的主要发病机制之一。增多的蛋白酶可通过参与炎症反应、降解细胞外基质、重塑气道等对肺组织造成破坏。近年来,中医药以蛋白酶-抗蛋白酶失衡为切入点,开展了大量的临床研究及基础实验,积累了丰硕的成果。The pathogenesis of chronic obstructive pulmonary disease(COPD)involves inflammation,oxidative stress,and protease-antiprotease imbalance,among which the protease-antiprotease imbalance is one of the main mechanisms of COPD.Increased protease can damage the lung tissue by participating in inflammation,degrading extracellular matrix,and remodeling airway.In recent years,a large number of clinical trials and basic studies have been carried out with protease-antiprotease imbalance as a breakthrough point,accumulating fruitful results.

关 键 词：慢性阻塞性肺疾病 蛋白酶-抗蛋白酶失衡 发病机制 临床研究 基础实验 中医药 研究进展 

分 类 号：R242[医药卫生—中医临床基础]